Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 74Pancreatic Neoplasms 54Carcinoma, Non-Small-Cell Lung 29Triple Negative Breast Neoplasms 27Neoplasm Metastasis 16Squamous Cell Carcinoma of Head and Neck 15Ovarian Neoplasms 12Neoplasms 12Lung Neoplasms 11Esophageal Squamous Cell Carcinoma 11Stomach Neoplasms 10Esophageal Neoplasms 10Head and Neck Neoplasms 9Uterine Cervical Neoplasms 7Melanoma 7Cholangiocarcinoma 7Small Cell Lung Carcinoma 6Recurrence 6Sarcoma 5Pancreatic Adenocarcinoma 5Inflammatory Breast Neoplasms 5Fallopian Tube Neoplasms 5Urinary Bladder Neoplasms 4Colorectal Neoplasms 4Advanced Pancreatic Cancer 4Carcinoma, Transitional Cell 3Carcinoma, Ovarian Epithelial 3Breast Neoplasms, Male 3Adenocarcinoma 3Uveal Melanoma 2

Interventions

durvalumab 1Gemcitabine 1Cisplatin 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Resectable Biliary Tract Cancer × Albumin-Bound Paclitaxel × Clear all
NCT05640791 2022-12-07

Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
40 enrolled
Gastrointestinal

Resectable Biliary Tract Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡